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Cigarette smoking is highly correlated with the onset of a variety of human cancers, and continued smokingis known to abrogate
thebeneﬁcial eﬀects ofcancertherapy. Whiletobacco smokecontainshundreds ofmoleculesthatareknowncarcinogens,nicotine,
the main addictive component of tobacco smoke, is not carcinogenic. At the same time, nicotine has been shown to promote
cell proliferation, angiogenesis, and epithelial-mesenchymal transition, leading to enhanced tumor growth and metastasis. These
eﬀects of nicotine are mediated through the nicotinic acetylcholine receptors that are expressed on a variety of neuronal and
nonneuronal cells. Speciﬁc signal transduction cascades that emanate from diﬀerent nAChR subunits or subunit combinations
facilitate the proliferative and prosurvival functions of nicotine. Nicotinic acetylcholine receptors appear to stimulate many
downstreamsignalingcascadesinduced bygrowthfactorsandmitogens.Ithasbeen suggested thatantagonistsofnAChRsignaling
might have antitumor eﬀects and might open new avenues for combating tobacco-related cancer. This paper examines the
historical data connecting nicotine tumor progression and the recent eﬀorts to target the nicotinic acetylcholine receptors to
combat cancer.
1.Introduction
Smoking is a major risk factor associated with the develop-
ment and progression of a variety of cancers [1]. Smoking is
estimated to account for approximately 4-5 million deaths
worldwide and approximately 443,000 deaths each year in
the United States alone [2, 3]. Suﬃcient evidence has accu-
mulated to conclude that tobacco smoking caused cancers
not only of the lung, but also of the lower urinary tract
including the renal pelvis and bladder, upper aero-digestive
tract including oral cavity, pharynx, larynx, and esophagus,
and pancreas [2, 4]. Recent lines of evidence have showed
that smoking tobacco can also cause cancers of the nasal
cavity, paranasal sinus, nasopharynx, stomach, liver, kidney,
cervix, uterus, breast, adenocarcinoma of the esophagus,
a n dm y e l o i dl e u k e m i a[ 2]. Of the thousands of chemicals
in tobacco smoke, polycyclic aromatic hydrocarbons and
nicotine-derived nitrosamines have been identiﬁed as the
majorandpotentcarcinogens[5,6].Themetabolitesofthese
agentsform DNAadductsand cause mutationsin vital genes
like Rb, p53, and K-Ras in smokers [7–9].
While the induction of these cancers is mediated by
tobacco-speciﬁc nitrosamines as well as other carcinogens
present in the tobacco smoke, it is becoming clear that
signaling through the nicotinic acetylcholine receptors con-
tribute to the growth, progression, and metastasis of a
variety of cancers. Nicotine, which is the major addic-
tive component of tobacco smoke, acts through nicotinic
acetylcholine receptors (nAChR) [9–11], but is not thought
to be carcinogenic. The expression of nAChRs in central
and peripheral nervous system is associated with smoking
dependence and addiction [12]. It was generally believed
that nAChRs are only expressed in nervous system and at
neuromuscular junctions (muscle type nAChRs). However,
the discovery of widespread expression of nAChRs in
mammalian cells, including cancers, suggested its direct
role in cancer progression [13–15]. This paper deals with
certainaspectsofnicotinicreceptorsignalinginnonneuronal2 Journal of Oncology
cells that lead to increased cell proliferation and survival,
angiogenesis, tumor growth, and metastasis.
2.NicotinicAcetylcholine ReceptorExpression
inNonneuronal Cells
nAChRs are a complex of ﬁve subunits forming hetero- or
homopentamers to form a central ion channel [16, 17]. The
neuronal nAChRs can be homomeric composed of α7, α8,
or α9 subunits or with the combinations of α2–α6o rα10
subunits with β2–β4 subunits (heteromeric nAChRs). The
muscle type nAChRs may be comprised of combinations
of α1 subunits with β1, γ, δ,o rε subunits [18]. Both
neuronal as well as muscle nAChR families are found to
be expressed in cancer cells [19]. Nicotine mimics acetyl-
choline by binding as an agonist to α subunit of nAChRs
[10]. Nicotine binds with higher aﬃnity to heteromeric
α4β2-nAChRs than to α7-nAChRs [20]. Higher binding
to α4β2-nAChRs results in desensitization of the receptor,
which could be the reason that α7-nAChR is the major
stimulator of cancer development and progression in vivo.
In addition to nicotine, tobacco-speciﬁc nitrosamines such
as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)
can also bind to α7-nAchR, and N-nitrosonornicotine
(NNN) binds to heteromeric αβ-nAChRs [21]. The aﬃnity
of NNK for the α7-nAChR was found to be 1,300 times
higher than nicotine, whereas the aﬃnity of NNN for
heteromeric αβ-nAChRs was 5,000 times higher than that of
nicotine [21, 22].
Since the discovery of ubiquitous presence of nAChRs in
mammalian cells,studiesfrommany laboratorieshavelinked
nAChRs with various pathological conditions including
tumor growth and angiogenesis [13, 23]. In earlier studies,
nicotinewasfound tostimulateendothelial-cellproliferation
via nAChR at concentrations lower than those obtained in
blood after smoking [24]. As described in the later part
of this paper, many studies have correlated the exposure
of nicotine or other tobacco smoke components with
induction of pathological neovascularization through the
activation of nAChR [23, 25]. Studies from our laboratory
have suggested that nicotine can enhance the growth and
metastasis of pre-established lung tumors [26]. Altogether,
these studies proposed the involvement of tobacco smoke
components in various aspects of tumorigenesis and vas-
cular dysfunctions in smokers. Extensive research by many
groups has successfully associated the physiological eﬀect
of nicotine and its derivatives with the direct activation
of nAChRs. Small cell lung carcinoma (SCLC) pulmonary
neuroendocrine cells (PNECs) and SCLC cells express high
levels of the α7-nAChR, whereas heteromeric nAChRs were
undetectable [27, 28]. At the same time, both hetero- and
homomeric nAChRs are found to be expressed in nonsmall
cell lung carcinoma cells of diﬀerent histologic subtypes
[19, 29]. Recently, diﬀerential expression pattern of ACHR
subunit gene was studied in NSCLC patients who were
smokers or never smokers. Higher expression of CHRNA6
and CHRNB3 combination was correlated with NSCLCs
in nonsmokers, whereas lower expression was correlated
with NSCLCs in smokers. Additionally, increased expression
of CHRNA1, CHRNA5, and CHRNA7 subunit genes was
correlated with short-term exposure to nicotine [30]. Nico-
tine stimulation contributed towards the growth of human
mesothelioma cells. Human biopsies of mesothelioma as
well as of normal pleural mesothelial cells were found to
express functional α7-nAChR [31, 32]. Studies from the
Russo laboratory have shown that inhibition of nAChRs
by α-cobratoxin (α-CBT) can inhibit the growth of A549
tumors in immunocompromised mice [33]. These ﬁndings
strengthen the hypothesis that modulation of nAChRs
upon chronic exposure to tobacco may contribute to the
development and progression of cancer. In the following
sections, we will summarize the ﬁndings to support the
hypothesis.
3.nAChRsSignaling in
Tumor Growth and Survival
Attempts have been made to elucidate the molecular events
that mediate nicotine-induced cell proliferation. Activation
of nAChR through nicotine or NNK has been found
to activate protein kinase C (PKC), the serine/threonine
kinase Raf-1, the mitogen-activated kinases ERK1 and
E R K 2 ,a n dt h et r a n s c r i p t i o nf a c t o r sF O S ,J U N ,a n dM Y C
through the selective activation of α7-nAChR in SCLC
[34]. Studies also demonstrated the stereospeciﬁcity of
nAChRs towards (−)-nicotine. It has been reported that
(−)-nicotine stimulated tumor cell proliferation via secre-
tion of the neurotransmitter serotonin, and the growth
stimulatory eﬀect of nicotine or NNK could be blocked
by selective serotonergic receptor antagonists [27, 35, 36].
In a recent report, the eﬀects of acute and repetitive
exposure to nicotine was shown to induce a neuronal-
like appearance in N417 SCLC cell line, which produced
bigger and more vascularized tumors in mice through
activation of CXCR4/CXCL12 axis. A prominent increase in
the expression ofCXCR4was observedin nAChR-dependent
manner in nicotine-treated cells [37]. NSCLC cell lines
from large-cell carcinoma, squamous-cell carcinoma, and
adenocarcinoma, all showed the activation of PI3K-AKT
pathway and NF-κB activation in response to nicotine or
NNK treatment [38, 39]. In addition, frequent loss of the
tumor suppressor gene FOXO3awas reported incarcinogen-
induced lung adenocarcinoma. In NNK-treated lung cancer
cells, restoration of FOXO3a in FOXO3a-deﬁcient cells
increases sensitivity to apoptosis caused by a DNA-damaging
intermediate of NNK. This study proposed that FOXO3a
might play a role in lung adenocarcinoma suppression
by providing a protective response to carcinogenic stress
[40].
Experiments from our laboratory have shown that
nicotine stimulation aﬀects various components of cell
cycle regulatory machinery [26, 29, 41]. Exposure to nico-
tine resulted in activation of Raf-1, induction of cyclin
D and cyclin E-associated kinase activity as well as Rb
phosphorylation, which led to the dissociation of E2F1
from Rb. Further, it was observed that stimulation with
nicotine caused the dissociation of Rb from E2F-responsive
proliferative promoters (cdc6 and cdc25A), while there wereJournal of Oncology 3
increased amounts of E2F1 bound to them. These molecular
events were correlated with increased proliferative eﬀects of
nicotine in NSCLC cell lines A549 (human bronchioalveolar
carcinoma), NCI-H23, NCI-H441 (lung adenocarcinoma),
and NCI-H226 (pleural eﬀusion squamous cell carcinoma)
as well as on primary normal human bronchial epithelial
cells (NHBEs), small airway epithelial cells (SAECs), human
aortic endothelial cells (HAECs), and human microvascular
endothelial cells from lung (HMEC-Ls). The mitogenic
eﬀects of nicotine were abrogated by α7 subunit antagonists,
α-bungarotoxin, and methylallyl aconitine (MAA), whereas
it was unaﬀected by α-lobeline (α4β2 subunit inhibitor)
or dihydro β-erythoidine (DHβE; α3β2a n dα4β2 subunit
inhibitor), suggesting that α7 subunits primarily mediated
the mitogenic eﬀects of nicotine in NSCLC cells. We
have further illustrated that upon nicotine stimulation, the
scaﬀoldingproteinβ-arrestin-1 formsacomplexwithnonre-
ceptor tyrosine kinase-Src and gets recruited to the nAChRs.
Depletion of β-arrestin-1 or Src prevented nicotine-induced
cell proliferation. These results suggested that α7-nAChR-
mediated stimulation of cell proliferation is through a
β-Arrestin-1-Src signaling axis in NSCLC [41]; (see also
Figure 1).
Other than lung cancer, activation of α7-nAChR and
heteromeric nAChRs expressing α3a n dα5 subunits have
been reported in oral and esophageal keratinocytes [22].
Similar to lung cancer cells, NNK was found to bind with
high aﬃnity to α7-nAChR, whereas NNN was found to bind
to heteromeric nAChRs with higher aﬃnity [22]. Esophageal
cancer-Het-1A cells stimulated with NNK or NNN showed
increased mRNA transcripts and expression of PCNA and
Bcl-2, and transcription factors GATA3, NF-κB, and STAT1.
However, induction of Ras-Raf-ERK1-ERK2 cascade, the
JAK2-STAT3 pathway and NF-κB activation was associated
with enhanced cell proliferation through these nitrosamines
inimmortalized oralepithelialcells[22].Inaddition,chronic
exposure of nicotine or environmental tobacco smoke on
oralkeratinocytesselectivelyupregulated α5- and α7-nAChR
subunits, resulting in intensiﬁed signaling responses to
nicotine [42].
The secreted mammalian Ly-6/urokinase plasminogen
activator receptor-related protein-1 (SLURP-1) is recently
identiﬁed as an endogenous ligand for the α7 subunit of
the nicotinic acetylcholine receptor (nAChR). The expres-
sion levels of SLURP1 and SLURP2 (secreted mammal-
ian Ly-6/urokinase plasminogen activator receptor-related
protein-2) were reduced in NNK-treated cells. Transfection
of the cells with SLURP1 or SLURP2 cDNA reduced the
nitrosamine-induced colony formation in soft agar while
inhibiting the growth of NNK-transformed keratinocytes
in mouse xenografts. SLURP1 bound to α7-nAChR and
SLURP2 bound to nAChRs expressing the α3 subunit [22,
43]. Similar results were demonstrated recently where HT-
29 human colon cancer cells treated with nicotine resulted
in increased cell proliferation and a marked reduction in
the protein expression of SLURP1 via α7-nAChRs acti-
vation [44]. Recently, nicotine mediated upregulation of
FOXM1 expression was found in primary oral keratinocytes
which was associated with induction of genomic instability.
A centrosomal protein CEP55 as well as a DNA helicase
and putative stem cell marker HELLS, were found to be
novel targets of nicotine-induced FOXM1 expression and
correlated with oral cancer progression [45].
A role of nAChR has been demonstrated in breast cancer
progression as well. Experiments with human mammary
epithelial-like MCF10A or cancerous MCF7 cells revealed
that treatment of these cells with nicotine enhances the
activity of protein kinase C (PKC) alpha with cdc42 as a
downstream target for nicotine-induced proliferation and
migration [46]. It has also been suggested that nicotine-
induced proliferation of human breast cancer cell is depen-
dent on α9-nAChR and cyclin D3 expression [47]. The
eﬀects of nicotine on a population of cancer stem cells in
MCF-7 human breast cancer cells were examined, using
aldehyde dehydrogenase (ALDH) as a stem cell marker. This
study found that nicotine increases the stem cell population
via α7-nAChR and the PKC-Notch dependent pathway
[48].
Apart from direct responses through nAChRs, indirect
signaling events may also contribute to nicotine-induced
tumor growth and survival. Since nAChRs are cation chan-
nels, it can stimulate signaling cascades by the inﬂux of Ca2+
through the opened α7-nAChR [49]. Ca2+ channel blockers
are shown to signiﬁcantly reduce DNA synthesis in response
to nicotine or NNK in SCLCs [49]. Also, nAChR-mediated
systemic increase in stress neurotransmitters, adrenaline,
and noradrenaline, which are β-adrenergic agonists, are also
shown to stimulate β-adrenergic receptor-initiated cAMP
signaling and transactivation of EGFR cascade through
EGF secretion in NNK-treated small airway epithelial cells
[50, 51]. Nicotine is found to induce systemic or cellular
increase in noradrenaline and signiﬁcantly enhance the
growth and angiogenesis of pancreatic, gastric, and colon
cancer-xenografts with increased expression of ERK1-ERK2,
COX2, prostaglandin E2, VEGF, and transactivation of
β-adrenergic as well as EGFR signaling in colon cancer
cells [52–55]. Activation of ERK1-ERK2 and STAT3 in
response to nicotine has also beenreported in bladdercancer
cells downstream of nAChRs and β-adrenergic receptors
[56]. Importantly, apart from nAChRs, direct interaction
of NNK with β-adrenergic receptor has been proposed
as a novel mechanism, which may signiﬁcantly enhance
the high cancer-causing potential of these nitrosamines
[50, 57]. Similar to the activation via neurotransmitters,
NNK binding to β-adrenergic receptor was also found
to activate adenylyl cyclase-cAMP-PKA-CREB cascade and
transactivation of EFGR [58]. Additionally, an additive eﬀect
of estrogen receptors and nAChRs was also demonstrated
in promoting the growth of A549 tumors in athymic nude
mice. Cotreatment of nicotine and estradiol resulted in
increased cell proliferation as well as VEGF secretion from
cancer cells, leading to increased tumor growth as well
as microvascular density within the tumor [59]. Recently,
the chronic exposure to estrogen and NNK was shown
to have synergistic eﬀects on cell proliferation and pro-
duction of noradrenaline and adrenaline, by upregulating
α7-nAChRs in immortalized small airway epithelial cells
[60].4 Journal of Oncology
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Figure1:AschematicofnAChR-mediatedregulationofdiversetumorigenicprocesses.nAChRsareactivated bytobacco smokecomponents
like NNN, NNK, and nicotine with diﬀerent aﬃnity. Induced nAChRs activate several downstream signaling pathways involved in cell
proliferation, inhibition of apoptosis, metastasis, and angiogenesis in a variety of cancer and primary cells. Agonist binding to nAChR
formscomplex with β-arrestin andSrcandresults in Raf-1 activation. Activated Raf-1 phosphorylates andinactivates Rb tumor-suppressor-
function. These in turn results in E2F-1-mediated transcriptional upregulation of target genes involved in cell proliferation, angiogenesis,
and inhibition of apoptosis. Downstream eﬀect of nAChR activation is also indirectly supported by the activation of β-adrenergic receptor
(β-AR) signaling. Nicotine exposure directly results in metastatic dissemination of primary tumor by inducing epithelial to mesenchymal
transition (EMT) in cancer cells.
4.nAChRsSignaling inCell Survivaland
Resistanceto Apoptosis
In addition to the eﬀect on tumor growth, epidemiological
and clinical data implicate that in patients with cancer,
continued smoking causes resistance to therapy by blocking
the induction of apoptosis. Various studies have linked the
activation of nAChR resulting in inhibition of apoptotic
pathways. In SCLC cells, NNK was shown to phosphorylate
Bcl-2 at Ser70 which promoted its interaction with c-Myc
that signiﬁcantly enhanced the half-life of the c-Myc protein
[61]. This functional cooperation of Bcl2 and c-Myc resulted
in promoting cell survival and proliferation. This eﬀect
could be blocked by the PKC inhibitor staurosporin, the
ERK1-ERK2 inhibitor PD98059 or silencing of MYC [61,
62]. Additionally, mesothelioma cells also showed nicotine-
stimulated proliferation through α7-nAChR-mediated Ca2+-
dependent activation of the ERK1-ERK2 cascade and inhib-
ited apoptosis by induction of NF-κB and phosphorylation
of BAD at Ser112 (Bcl-2 antagonist of cell death) [32]. In
NSCLCs, constitutive activation of AKT is associated with
lung cancer cell survival and resistance to chemotherapy
and radiation [63]. Similarly, nicotine or NNK exposure
displayed AKT-mediated growth and NF-κB-mediated resis-
tance to apoptosis in human airway epithelial cells as well
as lung cancer cells [38, 39]. Further, activated AKT could
directly phosphorylate Bax in vitro in nicotine treated cells.
Treatment of cells with the phosphatidylinositol 3-kinase
(PI3K) inhibitor LY294002 or speciﬁc depletion of AKT was
shown to block both nicotine-induced Bax phosphorylation
and cisplatin resistance in NSCLC cells [64].
In addition to these signaling events, results from our
laboratory revealed a signiﬁcant role for the IAP pro-
teins XIAP and survivin in nicotine-mediated chemoresis-
tance in NSCLCs in vitro. Chromatin immunoprecipitation
assays demonstrated that nicotine stimulation caused an
increased recruitment of E2F1 and concomitant dissociation
of retinoblastoma tumor suppressor protein (Rb) from
survivin promoter in NSCLC cells [65]. Moreover, ablation
of E2F1 levels caused abrogation of survivin expression
and protective eﬀects of nicotine against cisplatin-induced
apoptosis in A549 cells. In the above study, chemoprotective
eﬀect of nicotine was found to be mediated through α3/β4-
nAChR activation and could be abrogated by agonists of
these subunits. It was also found that nicotine stimulation
enhanced the levels of XIAP at the protein level. Nicotine
induces the activation of Akt, which is known to phosphory-
late XIAP and prevent its proteasome-mediated degradation
[66]. In agreement with this, an Akt inhibitor could abrogate
the antiapoptotic eﬀects of nicotine in A549 cells [65].
In other studies, the cooperative eﬀect of nicotine and
NNK was investigated for their transforming ability in vari-
ouslungepithelialorcancercells.Exposuretonicotineorthe
combination of nicotine and NNK for one week augmentedJournal of Oncology 5
Bcl-2 expression, accompanied by an increased resistance
to cisplatin-induced apoptosis [67]. This study also showed
that the combination treatment promoted cell prolifera-
tion and anchorage-independent growth as compared to
NNK exposure alone [67]. In another study, nicotine was
demonstrated to mediate prosurvival activity by Mcl-1
phosphorylation. Nicotine-induced Mcl-1 phosphorylation
signiﬁcantlyenhanced thehalf-life ofMcl-1,which conferred
long-termsurvival potential [68].SpeciﬁcdepletionofMcl-1
by RNA interference blocked nicotine-stimulated survival
and enhanced apoptotic cell death [67]. Nicotine-mediated
activation of α7-nAChR has also been linked with the
expression of PPARβ/δ protein by inhibiting AP-2α protein
expression and DNA binding activity to the PPARβ/δ gene
promoter [69]. Sp1 was found to modulate this process. α7-
nAChR antagonist and short interfering RNA against α7-
nAChR as well as inhibitors of phosphatidylinositol 3-kinase
(PI3K; wortmannin and LY294002) and mammalian target
of rapamycin (mTOR; rapamycin) blocked the expression
of PPARβ/δ protein demonstrating a novel mechanism by
which nicotine could promote human lung carcinoma cell
growth [69]. These studies show that signaling through
the nAChRs could promote cell proliferation and survival,
utilizing multiple signaling cascades.
5.nAChRsand TumorAngiogenesis
Angiogenesis, the formation of new blood vessels from
pre-existing vasculature, is a complex multistep process
involved in a number of physiological processes such as
wound healing, embryogenesis and reproduction. In addi-
tion, angiogenesis is necessary for the sustained growth
of the primary tumor as well as metastatic dissemination.
Nicotine has been shown to enhance angiogenesis in many
experimentalsystemsandanimalmodels.Theproangiogenic
activity of nicotine is mediated by nicotinic acetylcholine
receptors, particularly α7 subunit. The pioneering study by
Villablanca (1998) demonstrated the ability of nicotine to
induce endothelial cell proliferation [24]. This observation
was followed by the elegant studies from the John Cooke’s
laboratory suggesting a cholinergic pathway for nicotine-
induced angiogenesis where they demonstrated complete
inhibition of endothelial network formation using nons-
elective nAChR antagonist mecamylamine in an in vitro
angiogenesis model [25]. Although several nAChR isoforms
are expressed on endothelial cells, a similar inhibition was
obtained only with the selective α7-nAChR antagonist α-
bungarotoxin, conﬁrming the speciﬁc involvement of α7-
nAChR. Further, in vivo pharmacological inhibition of
nAChR and a genetic disruption of α7-nAChR expres-
sion signiﬁcantly inhibited inﬂammatory angiogenesis and
reduced ischemia-induced angiogenesis and tumor growth.
They also provided anatomic and functional evidence for
nicotine-induced angiogenesis and arteriogenesis when they
observed that nicotine accelerated the growth of tumor and
atheroma in association with increased neovascularization
[23].
Nicotine increased endothelial-cell growth and tube
formation in vitro, and accelerated ﬁbrovascular growth
in vivo. In a mouse model of hind-limb ischemia, nicotine
increased capillary and collateral growth, and enhanced
tissue perfusion. These eﬀects of nicotine were mediated
through nicotinicacetylcholine receptorsat nicotineconcen-
trations that are pathophysiologically relevant and suggested
a possible role for the endothelial production of nitric oxide,
prostacyclin, and vascular endothelial growth factor [70–
74]. Nicotine has been demonstrated to stimulate postnatal
angiogenesis, having an antiapoptotic eﬀect on endothelial
cells. It was observed that nicotine stimulated postnatal vas-
culogenesis on endothelial progenitor cells (EPCs) [75]. The
eﬀect of nicotine on EPC survival was signiﬁcantly enhanced
under serum starvation. Furthermore, the antiapoptotic
eﬀect of nicotine was blocked completely by nicotinic
acetylcholine receptor (nAChR) antagonist hexamethonium
bromide [75].
Recent studies have shown that apart from cigarette
smoking, exposure to secondhand smoke also could induce
angiogenesis. A positive correlation between secondhand
smoke exposure and concentrations of nicotine in the body
wasestablishedafteranalyzingtwenty-twostudiesmeasuring
the biological eﬀects of nicotine [76]. Further, it was found
that the levels of nicotine exposure from secondhand smoke
were comparable to those of active smokers. In a mouse
model where Lewis lung cancer cells were implanted subcu-
taneously into mice, which were then exposed to sidestream
smoke (SHS) or clean room air and administered vehicle or
mecamylamine (an inhibitor of nAChR); SHS signiﬁcantly
increased tumor size, weight, capillary density, VEGF, and
MCP-1 levels, and circulating endothelial progenitor cells
(EPC). Mecamylamine partially inhibited the eﬀects of SHS
ontheseangiogenicprocessesandnearlyabolishedtheeﬀects
of SHS on tumor capillary density suggesting that nicotine
mediated the eﬀects of SHS on tumor angiogenesis and
growth [77].
Several recent studies have implicated that nicotine-
induced angiogenesis could be mediated by growth stabi-
lization and transmigration of endothelial progenitor cells
(EPC) [75, 78, 79]. Nicotine accelerated the growth of
syngenic colon cancer CMT93 cells when grown subcuta-
neously in mice by inducing angiogenesis via bone marrow
derived EPCs [78]. To determine if the angiogenic eﬀects
of nicotine is mediated by EPC mobilization, Heeschen
et al. used a model of mouse parabiosis and found that
nicotine enhances EPC mobilization into the vasculature of
the ischemic tissue. This eﬀect may be due to the direct
actions of nicotine on EPC proliferation, migration and/or
mobilization as suggested by in vitro models [80]an dplas m a
markers usedin theinvestigation[79].They alsonoticedthat
in the absence of acute ischemia, nicotine did not stimulate
EPC mobilization. The activation of nAChRs in response to
ischemia induced the release of proangiogenic factors like
VEGF and stem cell derived factor-1, both ofwhich are regu-
lated by hypoxia, which in turn facilitates EPC mobilization
[81]. Evidence from another study also demonstrated that
nicotine promotes angiogenesis via stimulation of nAChR-
dependent endothelial cell migration. nAChR antagonism
not only abolished nicotine-induced human microvascular
endothelial cells (HMVEC) migration but also abolished6 Journal of Oncology
migration induced by bFGF and attenuated migration
induced by VEGF. Transcriptional proﬁling identiﬁed gene
expression programs which were concordantly regulated by
all3angiogens(nicotine,VEGF,andbFGF),anotablefeature
of which includes corepression of thioredoxin-interacting
protein (TXNIP), endogenous inhibitor of the redox regu-
lator thioredoxin. Furthermore, TXNIP repression by all 3
angiogensinducedthioredoxinactivity.Interestingly,nAChR
antagonism abrogates growth factor (VEGF- and bFGF-)
mediated induction of thioredoxin activity suggesting the
requirement of nAChR activation in endothelial cell migra-
tion, a key angiogenesis event [82].
The proangiogenic eﬀects of nicotine have been found
to be mediated by α7-nAChR on endothelial cells by acti-
vating ERK/MAP kinase pathway, PI3 kinase/Akt pathway,
and NF-κB[ 23, 25, 83, 84]. Further, nicotine has been
shown to induce the proangiogenic factors like VEGF
and HIF-1α in NSCLC cell lines [85]. Pharmacologically
blocking nAChR-mediated signaling cascades, including the
C a 2 + / c a l m o d u l i n ,S r c ,p r o t e i nk i n a s eC ,P I 3 K / A k t ,M A P K /
ERK1/2, mTOR pathways, signiﬁcantly attenuated nicotine-
induced upregulation of HIF-1α. These proangiogenic and
invasive eﬀects of nicotine were partially abrogated by
depleting HIF-1α using siRNA techniques. Additionally,
nicotine could promote angiogenesis of gastric cancers
by upregulating COX2 and VEGFR2 [86]. Nicotine also
enhanced the activity of matrix metalloproteinase 2 and 9
and expression of plasminogen activators in a COX2 and
VEGFR2-dependent manner. The proangiogenic eﬀect of
nicotine has been shown to be dependent on Src activity by
our laboratory [41]. The inhibition of Src, using chemical
inhibitors or siRNA has been shown to inhibit endothelial
cell proliferation, migration, and angiogenic tubule forma-
tion on matrigel. As mentioned earlier, studies from our
laboratory suggest that the scaﬀolding protein β-arrestin-1
causes the activation of Src. Oligomeric complex comprising
of nAChR, β-arrestin-1, and Src is vital for nAChR signaling.
In addition, depletion of β-arrestin-1 caused abrogation of
endothelial cell proliferation and angiogenic tubule forma-
tion [29, 41]. These data suggest that nicotine behaves in a
manner analogous to growth factors and induces cell cycle
progression in endothelial cells.
6.nAChRsin EMTand TumorMetastasis
Epithelial to mesenchymal transition (EMT) is a biolog-
ical process that allows a polarized epithelial cell, which
normally interacts with the basement membrane through
its basal surface, to undergo multiple biochemical changes
with a signature of more advanced and less diﬀerentiated
cancer that allow it to assume a mesenchymal phenotype.
This enhanced migratory capacity, invasiveness, resistance
to apoptosis, and greatly increased production of ECM
components [87–89]. This process results in degradation of
basement membrane and the formation of a mesenchymal
like cell, which can migrate away from the epithelial layer
in which it originated [88]. Epithelial to mesenchymal
transition (EMT) is involved in tumor progression from
noninvasive tumor cells into metastatic carcinomas. Recent
studies from our laboratory demonstrated that nicotine can
induceinvasion and migration in cell lines derivedfrom lung
cancer, breast cancer, and pancreatic cancer via α7-nAChR-
mediated signal transduction pathways[90].The proinvasive
eﬀects of nicotine were mediated by α7-nAChR in lung
cancer cells while α7-nAChR and DhβEs e n s i t i v en A C h R s
mediated invasion of breast cancer cells. Nicotine was also
found to inhibit anoikis in lung airway epithelial cells.
Further, nicotine could induce changes in gene expression
consistent with EMT. Long-term treatment of lung cancer
and breast cancer cells with nicotine was found to diminish
levels of epithelial markers namely β-catenin and E-cadherin
and upregulate mesenchymal proteins like ﬁbronectin and
vimentin, indicative of disruption of cell-cell contacts and
increased motility [90].
In addition to facilitating EMT, nicotine and NNK
have been shown to aﬀect various aspects of tumor cell
invasion and migration. For example, both nicotine and
NNK are shown to promote the invasion of NSCLC by
phosphorylation of μ and m-calpains [62]. Several lines of
evidence show that calpain-mediated proteolysis mediates
various aspects of cell physiology including cell migration
and invasion. Nicotine was found to induce phosphorylation
of both μ and m-calpains via α7-nAChR; the binding of
nicotine to α7-nAChR in turn was found to activate Src
and PKC-iota, leading to enhanced invasion and migration
of NSCLC cell line H1299. Similarly, NNK also could
promote invasion and migration through phosphorylation
of μ and m-calpains in a α7-nAChR-dependent fashion
[62].
Several observations in patients suggest that those
exposed to tobacco carcinogens are more likely to develop
larger, more vascularized tumors with a high propensity
for metastatic spread and resistance to chemotherapy [90].
About30%oflungcancerpatientswhoaresmokerscontinue
to smoke after they have been diagnosed [91], which might
result in increased adverse medical consequences such as
increased tumor progression, development of a second
cancer, greater recurrence, greater cancer-related mortality
and reduced quality of life [92, 93]. While these studies
demonstrate a role for tobacco carcinogens in the initiation,
growth, and progression of cancers, the relative contribution
of nicotine by itself to these processes is not well explored.
A recent study from our laboratory demonstrated that
nicotine by itself can induce the growth and metastasis
of tumors in immunocompetent mice, independent of
othertobaccocarcinogens[26].Nicotineadministered either
intraperitonially or by commercially available transdermal
patches could substantially promote tumor growth. Similar
eﬀects were observed on implanted tumors as well as tumors
induced by tobacco carcinogen, NNK. Furthermore, mice
exposed to nicotine showed signiﬁcantly enhanced lung
metastasis as well as tumor recurrence after surgical removal
of the primary tumor, indicating that nicotine can enhance
the growth and metastasis of pre-established lung tumors
[26].As mentionedearlier, repetitiveexposure tonicotineon
SCLC-N417 cells resulted in neuronal-like appearance along
with increased adhesion to the extracellular matrix. These
changes were accompanied by enhanced migration throughJournal of Oncology 7
collagen matrices and adhesion to and transmigration across
lymphatic endothelial cell monolayers [37].
Accumulating evidence from epidemiological studies
suggest a strong association between smoking and pul-
monary metastatic disease in women with breast cancer
[94]. In a murine model of metastatic mammary cell
cancer, cigarette smoke exposure was associated with an
increase in the total pulmonary metastatic burden providing
experimental support foran adverse eﬀectof smoking onthe
metastatic process and suggesting a possible mechanism for
smokers’ increased breast cancer mortality [95]. In addition,
it was observed that cigarette smoking was correlated with
increased lymph node metastases at mastectomy in women
older than 50 years of age suggesting that tobacco usage
may potentiate the early spread of malignant disease [96].
Although numerous studies have indicated the role of nico-
tine exposure in tumor promotion, little is known about the
molecular mechanisms by which nicotine promoted breast
tumor development, especially on the metastatic process of
breast cancer. At least four diﬀerent subunits of nAChRs
including α5, α7, α9, and β4 are shown to be expressed in
breast cancer cells [46]. It has been demonstrated that in
addition to proliferative eﬀect, nicotine promoted migration
of breast cell lines (mammary epithelial cell line MCF10A
andbreastcancercelllineMCF7)throughasignalingcascade
involving PKC activation and its downstream eﬀector cdc42
[46]. Exposure to nicotine has shown to increase the
expression of α9-nAChR in breast cancer cells [47, 97].
Studies using a soft agar transforming assay and a mouse
xenograft model demonstrated that noncancerous human
breast epithelial cell line, MCF10A, could be neoplastically
transformed by exposure to either a cigarette smoke con-
densate or the tobacco speciﬁc carcinogen, NNK [98, 99].
In a recent study, α9-nAChR expression was silenced in
MDA-MB-231 breast cancer cells which resulted in reduced
proliferation and tumorigenic potential in both in vitro and
in vivo assays, indicating the role of α9-nAChR in breast
carcinogenesis [100].
Cigarette smoking has recently been recognized as a risk
factor for gastric cancer [101] and long-term exposure of
nicotine-induced EMT like changes in gastric cancer cell
lines by activating Erk/5-Lox signaling pathway [102]. A
study on the association between cigarette smoking and
pancreatic cancer showed that smokers had a signiﬁcantly
higher risk (70%) of developing pancreatic cancer compared
to nonsmokers [103–105]. Accumulating evidence suggests
that nicotine induces expression of osteopontin, a secreted
phosphoproteinthatconfersoncancercellsamigratory phe-
notype and activates signaling pathways that induce cell sur-
vival, proliferation, invasion, and metastasis. Rats exposed
to cigarette smoke showed a dose-dependent increase in
pancreatic osteopontin expression. In addition, analysis of
cancer tissues from invasive pancreatic ductal adenocarci-
noma (PDA) patients, the majority of whom were smokers,
showedthepresenceofsigniﬁcantamountsofosteopontinin
malignant ducts and the surrounding pancreatic acini [106].
Further studies suggested that nicotine contributes to PDA
metastasis by inducing MMP9 and VEGF expression and
osteopontin mediated these eﬀects [107]. An osteopontin
isoform, OPNc, is selectively inducible by nicotine and
is highly expressed in PDA tissues from smokers which
inducedtheexpression ofmonocylechemoattractant protein
(MCP-1) indicating a proinﬂammatory role of nicotine
[108]. Altogether, these results suggest that nicotine plays a
key role in the regulation of the complex cellular cascades
that modulate cell adhesion, invasion, and migration leading
to metastasis.
7.Discussionand Conclusions
Tobacco smoking is a well-documented risk factor for
many cancers. As summarized in Figure 1, nicotine, the
principal addictive component of tobacco smoke, as well
as other nitrosamines have been found to act through
nAChRs on nonneuronal cells to facilitate tumor growth,
angiogenesis, metastasis, survival, and chemoresistance by
regulating diverse signaling pathways. Binding of agonist
to nAChR facilitates the complex formation between the
receptor, scaﬀolding protein β-arrestin and tyrosine kinase
Src. Activation of Src was found to be important for cancer
as well as endothelial cell proliferation and angiogenic tube
formation in vitro.P r o l i f e r a t i v ee ﬀect of nAChR-activation
was also supported by indirect stimulation of β-adrenergic
receptor (β-AR) signaling. Further, chemotherapy-induced
apoptosis was found to be blocked by nicotine-induced
survivin expression as well as NF-κB activation. Activation
of nAChR is also correlated with EMT-like changes and
metastatic dissemination of primary tumor cells. Given the
ability of nicotine to aﬀect various aspects of tumor growth
and metastasis, antagonists of nAChR signaling might be
beneﬁcial in controlling the growth and progression of
tumors. Recently, alpha cobratoxin (α-CbT) has been shown
toblockthe growthofa variety ofNSCLCand mesothelioma
cell lines both in vitro and in vivo [109, 110]. The most
striking eﬀect of α-CbT was its ability to eﬀectively inhibit
the metastatic potential of lung cancer cells transplanted
into nude mice, indicating the possibility of using nAChR
antagonists as adjuvant therapy in preventing metastatic
spread. At the same time, the potential side eﬀects of
nAChR antagonists on the brain and central nervous system
need to be investigated before using them as a viable drug
for combating lung cancer. Moreover, the direct role of
nicotine alone on several aspects of tumorigenesis raises
the need to revisit the potential tumor promoting eﬀects of
nicotine-replacementtherapy.Also,themodulationeﬀectsof
secondhand smokeon nAChRsrequiredetailedinvestigation
in the future.
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